2016 - Fellow of the Royal Society of Canada Academy of Science
Member of the Association of American Physicians
His primary areas of investigation include Surgery, Anticoagulant, Anesthesia, Internal medicine and Heparin. His Surgery research incorporates themes from Aspirin and Clinical trial. His Anticoagulant study combines topics in areas such as Fibrinolytic agent, Warfarin and Intensive care medicine.
His biological study spans a wide range of topics, including Phases of clinical research, Randomized controlled trial, Dabigatran, Edoxaban and Hemostasis. His research integrates issues of Endocrinology and Cardiology in his study of Internal medicine. His Heparin research integrates issues from Discovery and development of direct thrombin inhibitors, Thrombin, Pharmacology and Fondaparinux.
His primary scientific interests are in Internal medicine, Anticoagulant, Heparin, Intensive care medicine and Thrombosis. His research in Internal medicine tackles topics such as Cardiology which are related to areas like Aspirin. He usually deals with Anticoagulant and limits it to topics linked to Anesthesia and Partial thromboplastin time.
In his study, Fibrin, Pharmacology, Biochemistry and Coagulation is strongly linked to Thrombin, which falls under the umbrella field of Heparin. His Intensive care medicine research is multidisciplinary, relying on both Venous thromboembolism, Clinical trial, Warfarin and Antithrombotic. Surgery covers Jeffrey I. Weitz research in Thrombosis.
Jeffrey I. Weitz mainly investigates Internal medicine, Thrombosis, Rivaroxaban, Venous thromboembolism and Intensive care medicine. His work in Internal medicine addresses subjects such as Cardiology, which are connected to disciplines such as Factor Xa Inhibitor. Jeffrey I. Weitz has researched Thrombosis in several fields, including Anticoagulant, Emergency medicine, Heparin and Dosing.
His work deals with themes such as Dabigatran, Aspirin and Randomized controlled trial, which intersect with Rivaroxaban. His studies in Apixaban integrate themes in fields like Hemostasis, Anesthesia and Venography. To a larger extent, Jeffrey I. Weitz studies Warfarin with the aim of understanding Edoxaban.
His scientific interests lie mostly in Internal medicine, Thrombosis, Stroke, Randomized controlled trial and Intensive care medicine. As part of his studies on Internal medicine, Jeffrey I. Weitz often connects relevant areas like Cardiology. His Thrombosis study incorporates themes from Factor XIa and Side effect.
His study focuses on the intersection of Intensive care medicine and fields such as Antithrombotic with connections in the field of Disease, Dosing, Review article, Heparin and Coagulation system. His Rivaroxaban study combines topics from a wide range of disciplines, such as Dabigatran, Placebo and Vitamin K antagonist. His research investigates the connection between Apixaban and topics such as Anesthesia that intersect with problems in TIMI.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Edoxaban versus warfarin in patients with atrial fibrillation
Robert P. Giugliano;Christian T. Ruff;Eugene Braunwald;Sabina A. Murphy.
The New England Journal of Medicine (2013)
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Christian T Ruff;Robert P Giugliano;Eugene Braunwald;Elaine B Hoffman.
The Lancet (2014)
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up
Behnood Bikdeli;Mahesh V. Madhavan;David Jimenez;Taylor Chuich.
Journal of the American College of Cardiology (2020)
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Giancarlo Agnelli;Harry R. Buller;Alexander Cohen;Madelyn Curto.
The New England Journal of Medicine (2013)
Derivation of a Simple Clinical Model to Categorize Patients Probability of Pulmonary Embolism: Increasing the Models Utility with the SimpliRED D-dimer
Philip S. Wells;David R. Anderson;Marc Rodger;Jeffrey S. Ginsberg.
Thrombosis and Haemostasis (2000)
Jeffrey I. Weitz.
The New England Journal of Medicine (1997)
Idarucizumab for Dabigatran Reversal
Charles V. Pollack;Paul A. Reilly;John Eikelboom;Stephan Glund.
The New England Journal of Medicine (2015)
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Mark Levine;Michael Gent;Jack Hirsh;Jacques Leclerc.
The New England Journal of Medicine (1996)
Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events
John W. Eikelboom;Jack Hirsh;Jeffrey I. Weitz;Marilyn Johnston.
A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.
Clive Kearon;Michael Gent;Michael Gent;Jack Hirsh;Jack Hirsh;Jeffrey Weitz.
The New England Journal of Medicine (1999)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: